ASCO Gastrointestinal Cancers Symposium
Meet with our team at ASCO GI
Posters and Presentations
Comprehensive genomic profiling of squamous cell carcinoma of unknown primary presenting with liver metastases
Time
11:45 AM – 1:15 PM PST
Abstract / Poster Number
755 M10
De-risking 1st line Chemotherapy-free Immune Checkpoint Inhibitor (ICI) use for patients with advanced Gastroesophageal Cancer (aGEJ) with Tumor Mutational Burden (TMB)
Time
11:45 AM – 1:15 PM PST
Abstract / Poster Number
407 K12
Relationship of Tumor Fraction in Circulating Tumor DNA (ctDNA) with Prognosis in Patients with Metastatic Pancreatic Cancer
Time
12:30 PM – 2:00 PM PST
Abstract / Poster Number
621 J8
Association of FGFR2 Structural Alterations in Intrahepatic Cholangiocarcinomas with Female Gender and Younger Age
Time
12:30 PM – 2:00 PM PST
Abstract / Poster Number
537 F4
Peri-Hilar Cholangiocarcinoma (phCCA): A Comparative Comprehensive Genomic Profiling Study
Time
12:30 PM – 2:00 PM PST
Abstract / Poster Number
542 F9
Characterizing outcomes of ERBB2-amplified biliary tract cancer.
Time
12:30 PM – 2:00 PM PST
Abstract / Poster Number
492 C17
Tumor genomics and sidedness to predict outcomes in metastatic colorectal cancer (mCRC)
Time
6:30 AM – 7:55 AM PST
Abstract / Poster Number
207 M15
Novel potential mechanisms of resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC)
Time
6:30 AM – 7:55 AM PST
Abstract / Poster Number
199 M7
POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI)
Time
6:30 AM – 7:55 AM PST
Abstract / Poster Number
194 M2
Relevant Publications
Colorectal Cancer
Negative hyper-selection of patients with HER2-positive and RAS wild-type metastatic colorectal cancer receiving dual HER2 blockade: the PRESSING-HER2 study.
Authors
Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, et al.
Journal
Clin Cancer Res. 2023.
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Authors
Quintanilha JCF, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, et al.
Journal
JAMA Netw Open. 2023;6(1):e2252244.
MKX-AS1 Gene Expression Associated with Variation in Drug Response to Oxaliplatin and Clinical Outcomes in Colorectal Cancer Patients.
Authors
Gonzalez RD, Small GW, Green AJ, Akhtari FS, Motsinger-Reif AA, Quintanilha JCF, et al.
Journal
Pharmaceuticals (Basel). 2023;16(5).
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Authors
Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, et al.
Journal
Nat Commun. 2022;13(1):5478.
BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.
Authors
Quintanilha JCF, Graf RP, Oxnard GR.
Journal
Oncologist. 2023;28(3):e171-e4.
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
Authors
Kennecke HF, O'Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, et al.
Journal
J Clin Oncol. 2023;41(2):233-42.
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Authors
Lonardi S, Nimeiri H, Xu C, Zollinger DR, Madison RW, Fine AD, et al.
Journal
Int J Mol Sci. 2022;23(19).
ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
Authors
Akhoundova D, Hussung S, Sivakumar S, Topfer A, Rechsteiner M, Kahraman A, et al.
Journal
Int J Cancer. 2022;151(12):2161-71.
Pancreatic Cancer
Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma.
Authors
Ashok Kumar P, Serinelli S, Zaccarini DJ, Huang R, Danziger N, Janovitz T, et al.
Journal
Front Oncol. 2023;13:1169586.
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Authors
Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, et al.
Journal
JCO Precis Oncol. 2023;7:e2300092.
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Authors
Chen KT, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, et al.
Journal
Oncologist. 2023;28(8):691-8.
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Authors
Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, et al.
Journal
Clin Cancer Res. 2023;29(22):4627-43.
Biliary Tract Cancers
Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Authors
Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A.
Journal
J Hepatol. 2023;78(3):614-26.
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Authors
Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, et al.
Journal
Clin Cancer Res. 2023;29(23):4853-62.
Gastroesophageal Cancer
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer.
Authors
Graf RP, Fisher V, Creeden J, Schrock AB, Ross JS, Nimeiri H, et al.
Journal
Cancer Res Commun. 2022;2(9):1037-48.
Relevant Pan/Multi-tumor Cancer Publications
Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types
Authors
Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, et al.
Journal
Clin Cancer Res. 2023.
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays.
Authors
Wang D, Elenbaas B, Murugesan K, Shah K, Montesion M, Gounaris I, et al.
Journal
NPJ Precis Oncol. 2023;7(1):103.
Genomic landscape of 891 RET fusions detected across diverse solid tumor types.
Authors
Parimi V, Tolba K, Danziger N, Kuang Z, Sun D, Lin DI, et al.
Journal
NPJ Precis Oncol. 2023;7(1):10.
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.
Authors
Kansara M, Bhardwaj N, Thavaneswaran S, Xu C, Lee JK, Chang LB, et al.
Journal
Mol Oncol. 2023;17(2):298-311.
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
Authors
Heilmann AM, Riess JW, McLaughlin-Drubin M, Huang RSP, Hjulstrom M, Creeden J, et al.
Journal
Oncologist. 2023.
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Authors
Murugesan K, Necchi A, Burn TC, Gjoerup O, Greenstein R, Krook M, et al.
Journal
ESMO Open. 2022;7(6):100641.
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol.
Authors
Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall'Olio FG, et al.
Journal
2023;34(1):111-20.
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Authors
Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, et al.
Journal
JCO Precis Oncol. 2023;7:e2300093.
Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering.
Authors
Huang RSP, Graf RP, Oxnard GR.
Journal
Cancer Cell. 2023;41(5):819-20.
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Authors
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, et al.
Journal
Nature. 2022;608(7923):609-17.
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Authors
Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, et al.
Journal
NPJ Precis Oncol. 2022;6(1):91.
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.
Authors
Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, et al.
Journal
JCO Precis Oncol. 2022;6:e2200261.